

Where Are We Now?

Targeted therapeutics are needed to improve the prognosis of patients with osteosarcoma.

Since the introduction of chemotherapy in the 1980s, 5-year survival for the often young patients with osteosarcoma has plateaued at about 50% to 60%. For patients with metastases, the outcomes remain particularly poor. By performing a serial analysis of a gene expression experiment comparing osteosarcomas with normal osteoblasts and mesenchymal stem cells, the authors identified the insulin-like growth factor (IGF) pathway and the transforming growth factor-β (TGF-β) pathway as possible targets for therapy. Since the effects of stimulation or inhibition of the TGF-β pathway on osteosarcoma cell proliferation is debatable [9], and the developed TGF-β pathway inhibiting agents elicit unwanted effects [13], we will focus on the possibility of targeting the IGF pathway in osteosarcoma.

The current paper emphasizes that the IGF pathway plays an important role in osteosarcoma pathogenesis, which is supported by other preclinical studies showing reduced proliferation in the majority of osteosarcoma cell lines [7] and xenografts [6] upon IGF 1 receptor (IGF-1R) inhibition. In addition, the peak incidence of osteosarcoma correlates with the increased levels of growth hormone and IGF ligands in puberty, and it has been described that the expression of several IGF pathway members (IGF-1R, IGF-1, growth arrest-specific 6, and IGFBP4) correlates with osteosarcoma prognosis [4, 7]. However, clinical trials demonstrate that only a small subset of osteosarcoma patients respond to IGF-1R antibodies [3]. This illustrates the general trend with IGF-1R inhibitors. Although preclinical models have shown promising results, evidence for their efficacy in large-scale randomized controlled trials is lacking. As a...
consequence, pharmaceutical companies have discontinued the production of all IGF pathway targeting agents.

Where Do We Need To Go?

The current paper emphasizes the importance of IGF signaling in the development of osteosarcomas. Despite the fact that only a subset of patients with osteosarcoma are sensitive to IGF-1R inhibition, the strong preclinical rationale deserves further clinical and translational exploration. Predictive biomarkers to identify the subset of patients that will benefit from IGF-directed therapy should be identified. The most obvious biomarker would be expression of the IGF-1R, but a Phase 2 trial with Cixutumumab (IGF-1R antibody) and Temsirolimus (mTOR inhibitor) in patients with bone and soft-tissue sarcomas showed that IGF-1R expression does not correlate with therapeutic response [11]. However, the search for biomarkers is ongoing, and several other biomarkers have been proposed, such as mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) and phosphorylated extracellular signal-regulated kinases (ERK) [5].

Besides the identification of predictive biomarkers, the efficacy of alternative methods to target the IGF pathway should be explored, such as tyrosine kinase inhibitors that target both the IGF-1R and the insulin receptor, given its crossreactivity. Once in vitro studies identify the best approach to target the IGF pathways, and once biomarkers have been identified, the next step would be small clinical trials to reevaluate the efficacy of IGF pathway inhibitors in patients with osteosarcoma. These clinical trials must incorporate a strong translational research program. Therefore, we should convince pharmaceutical companies to resume the production of IGF pathway inhibitors, especially the IGF-1R/insulin receptor dual inhibitors.

How Do We Get There?

One clinical trial with Linsitinib (a dual IGF-1R insulin receptor inhibitor) is currently being performed in Ewing sarcoma, where IGFBP3 is downregulated as a consequence of the Ewing sarcoma breakpoint region 1-Friend leukemia virus integration 1 fusion gene (EWSR1-FLI-1) [10] resulting in overactivity of the IGF pathway. Interestingly, IGF-1R inhibition seems promising in a subset of patients with Ewing sarcoma [3]. This EuroSARC study, led by Prof. Dr. Hassan from the University of Oxford, aims to identify predictive biomarkers by incorporating a strong translational research program in this clinical trial. The biomarkers that will be identified in the EuroSARC study should be tested in other tumors including osteosarcoma, and as mentioned above, new trials for osteosarcoma, similar to this trial in Ewing sarcoma, should be conducted. The clinical trials that have been performed in osteosarcoma thus far have two major limitations. First, all the studies involved IGF-1R monoclonal antibodies. It is known that signaling via the insulin receptor can circumvent IGF-1R inhibition [2]. Indeed, it was shown in osteosarcoma cells that dual inhibition of IGF-1R and insulin receptor is more effective than IGF-1R inhibition alone [1]. Therefore, results from clinical studies with dual inhibitors are warranted. Second, in the clinical trials conducted so far, IGF-1R-targeting antibodies were administered as a monotherapy to patients that failed complete remission upon chemotherapy. IGF-1R inhibitors should be tested in combination with chemotherapeutic agents, as it has been described that the ligand IGF-2 is upregulated in patients in response to chemotherapy [12] and that in osteosarcoma cell lines IGF-1R inhibition can enhance the effect of doxorubicin and radiotherapy [8].

The current paper strengthens the view that the IGF pathway can be an effective target for therapy in osteosarcoma, thereby emphasizing the need for the industrial facilitation of clinical trials with IGF-1R/insulin
receptor dual inhibitors combined with chemotherapy, in which a strong translational program is embedded for predictive biomarker identification in osteosarcoma patients.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Avnet S, Sciaccia L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. *Cancer Res.* 2009;69:2443–2452.
2. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, Epstein D, Pachter JA, Miglarese MR. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor I receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. *Mol Cancer Ther.* 2010;9:2652–2664.
3. Fleuren ED, Versleijen-Jonkers YM, Boerman OC, van der Graaf WT. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives. *Biochim Biophys Acta.* 2014;1845:266–276.
4. Jentzsch T, Robl B, Huxmann M, Bode-Lesniewska B, Fuchs B. Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray. *Anticancer Res.* 2014;34:3881–3889.
5. King H, Alekis T, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? *Cancer Treat Rev.* 2014;40:1096–1105.
6. Kolb EA, Kamara D, Zhang W, Lin J, Hingorani P, Baker L, Houghton P, Gorlick R. R1507, a fully human monoclonal antibody targeting IGF-1R, is effective alone and in combination with rapamycin in inhibiting growth of osteosarcoma xenografts. *Pediatr Blood Cancer.* 2010;55:67–75.
7. Kuijjer ML, Peterse EF, van den Akker BE, Briain-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. *BMC Cancer.* 2013;13:245.
8. Luk F, Yu Y, Walsh WR, Yang JL. IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines. *Cancer Invest.* 2011;29:521–532.
9. Moehseny AB, Cai Y, Kuijjer M, Xiao W, van den Akker B, Jacobs R, ten Dijke P, Hogendoorn PC, Cleton-Jansen AM. The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. *Eur J Cancer.* 2012;48:3429–3438.
10. Prieur A, Tirole F, Cohen P, Delatitre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. *Mol Cell Biol.* 2004;24:7275–7283.
11. Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulinik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adams K, Van Tine BA, Brockstein B, Yin V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: A multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2013;14:371–382.
12. Shimizu T, Sugihara E, Yamaguchi-Iwai S, Tamaki S, Koyama Y, Kamei W, Ueki A, Ishikawa T, Chiyoda T, Osaka S, Onishi N, Ikeda H, Kamei J, Matsuo K, Fukushima Y, Nagai T, Toguchida J, Toyama Y, Muto A, Saya H. IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress. *Cancer Res.* 2014;74:6531–6541.
13. ten Dijke P, van Dam H. 14-3-3zeta turns TGF-beta to the dark side. *Cancer Cell.* 2015;27:151–153.